The HELIOS trial protocol: A Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia

Future Oncology

Volumn 11, Issue 1, 2015, Pages 51-59

  Hallek, Michael ^a   Kay, Neil E ^b   Osterborg, Anders ^c   Chanan Khan, Asher A ^d   Mahler, Michelle ^e   Salman, Mariya ^e   Wan, Ying ^e   Sun, Steven ^e   Zhuang, Sen Hong ^e   Howes, Angela ^f  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MAYO CLINIC   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d MAYO CLINIC   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

B cell receptor signaling; bendamustine; Bruton's tyrosine kinase; chronic lymphocytic leukemia; ibrutinib; rituximab; small lymphocytic lymphoma

Indexed keywords

BENDAMUSTINE; IBRUTINIB; PLACEBO; RITUXIMAB; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE; MONOCLONAL ANTIBODY; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; CHEMISTRY; CLINICAL TRIAL; FEMALE; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; PYRAZOLES; PYRIMIDINES;

EID: 84921033879     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.119     Document Type: Article

References (28)

1. Burger JA. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr. Hematol. Malig. Rep. 7(1), 26-33 (2012).
2. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline. treatment strategies. Blood 122(23), 3723-3734 (2013).
3. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117(19), 5019-5032 (2011).
4. Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J. Clin. Oncol. 29(5), 544-550 (2011).
5. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12), 5446-5456 (2008).
6. Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343(24), 1750-1757 (2000).
7. Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet 376(9747), 1164-1174 (2010).
8. Badoux XC, Keating MJ, Wang X et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11), 3016-3024 (2011).
9. Fischer K, Cramer P, Busch R et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol.29(26), 3559-3566 (2011).
10. Zaja F, Mian M, Volpetti S et al. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. Am. J. Hematol. 88(11), 955-960 (2013).
11. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 22(Suppl. 6), vi50-vi54 (2011).
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas Version I. 2013. National Comprehensive Cancer Network Website. www.nccn.org
13. Honigberg LA, Smith AM, Sirisawad M et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in modes of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA. 107(29), 13075-13080 (2010).
14. Khan WN. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol. Res. 23(2-3), 147-156 (2001).
15. Wiestner A. Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J. Clin. Oncol. 31(1), 128-130 (2013).
16. de Rooij MFM, Kuil A, Geest C et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119(11), 2590-2594 (2012).
17. Pan Z, Scheerens H, Li SJ et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem. Med. Chem. 2(1), 58-61 (2007).
18. Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31(1), 88-94 (2012).
19. Byrd JC, Furman RR, Coutre SE et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369(1), 32-42 (2013).
20. O'Brien S, Furman RR, Coutre SE et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, Phase 1b/2 trial. Lancet Oncol. 15(1), 48-58 (2013).
21. Hallek M, Cheson BD, Catovsky D et al. Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes. Blood (2012). http://bloodjournal.hematologylibrary.org
22. Woyach JA, Smucker K, Smith LL et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 123(12), 1810-1817 (2014).
23. Jaglowski SM, Jones JA, Flynn JM et al. A Phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J. Clin. Oncol. 30(Suppl.) Abstract 6508, (2012).
24. Brown JR, Barrientos JC, Barr PM et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a Phase 1b study. Blood 122(21), Abstract 525 (2013).
25. Burger JA, Keating MJ, Wierda WG et al. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a Phase II trial in 40 patients. Blood 122(21), Abstract 675 (2013).
26. Hillmen P. Using the biology of chronic lymphocytic leukemia to choose treatment. Hematology Am. Soc. Hematol. Educ. Program 2011, 104-109 (2011).
27. Maddocks KJ, Lin TS. Update in the management of chronic lymphocytic leukemia. J. Hematol. Oncol. 2(29), 1-8 (2009).
28. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 35(3), 549-556 (1979).